Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 2Breast 2Sarcoma 1

Conditions

Oligodendroglioma 1Liposarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 48Bevacizumab 29Carmustine 17Erlotinib Hydrochloride 16Radiotherapy 14Irinotecan 14Surgical Procedures, Operative 10Sirolimus 10Imatinib Mesylate 10Carboplatin 10Sorafenib 9O(6)-benzylguanine 9Filgrastim 9Etoposide 8temsirolimus 7sargramostim 7Radiosurgery 7Radiation 7Procarbazine 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7aldesleukin 6Topotecan 6Thalidomide 6Vorinostat 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Hydroxyurea 5Gefitinib 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × cabazitaxel × Sarcoma × Clear all
NCT01740570 2018-01-19

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡